Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| polymers | 2486 | 304-55-2 |
None
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 20 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| S (Water solubility) | 288 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKC,AXL,BMX,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHUK,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT1,FLT3,FLT4,GRK2,GRK3,GSK3B,IGF1R,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM1,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 | 78 | |||
| kinase-selectivity-class | AXL,BMX,BRAF,CDK4,CDK9,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,MAPK7,PRKDC,STK33,SYK,TEK,TGFBR1,ZAP70 | 18 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 30, 1991 | FDA | RECORDATI RARE |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000931 | Antidotes |
| MeSH PA | D002614 | Chelating Agents |
| MeSH PA | D020011 | Protective Agents |
| MeSH PA | D064449 | Sequestering Agents |
| FDA MoA | N0000175962 | Lead Chelating Activity |
| FDA EPC | N0000175963 | Lead Chelator |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:38161 | chelator |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Accidental poisoning by lead and its compounds and fumes | indication | 216777009 |
None
None
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.29 | acidic |
| pKa2 | 3.76 | acidic |
| pKa3 | 9.66 | acidic |
| pKa4 | 11.78 | acidic |
None
None
None
| ID | Source |
|---|---|
| 4019174 | VUID |
| N0000147417 | NUI |
| D00572 | KEGG_DRUG |
| 4019174 | VANDF |
| C0012384 | UMLSCUI |
| CHEBI:63623 | CHEBI |
| CHEMBL1201073 | ChEMBL_ID |
| DB00566 | DRUGBANK_ID |
| D004113 | MESH_DESCRIPTOR_UI |
| 2724354 | PUBCHEM_CID |
| 4621 | INN_ID |
| DX1U2629QE | UNII |
| 3446 | RXNORM |
| 194288 | MMSL |
| 5516 | MMSL |
| NOCODE | MMSL |
| d01417 | MMSL |
| 003583 | NDDF |
| 109104002 | SNOMEDCT_US |
| 397224000 | SNOMEDCT_US |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Chemet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55292-201 | CAPSULE | 100 mg | ORAL | NDA | 29 sections |
| NephroScan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71083-0020 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | NDA | 24 sections |